0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Tisagenlecleucel is indicated for the treatment of: - Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
ND
Nieprzydzielony
EMA approval status :
Approved
EMA approval date :
2018-08-23
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
Yes